CATB Catabasis Pharmaceuticals, Inc. Stock Quote

CATB [NASD]

Index	-	P/E	-	EPS (ttm)	-2.04	Insider Own	0.11%	Shs Outstand	20.10M	Perf Week	-17.34%
Market Cap	55.51M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	0.00%	Shs Float	20.06M	Perf Month	-37.43%
Income	-37.30M	PEG	-	EPS next Q	-0.18	Inst Own	38.40%	Short Float	12.95%	Perf Quarter	-17.34%
Sales	-	P/S	-	EPS this Y	13.40%	Inst Trans	-6.53%	Short Ratio	0.43	Perf Half Y	-64.27%
Book/sh	2.02	P/B	1.11	EPS next Y	3.00%	ROA	-67.60%	Target Price	-	Perf Year	-57.66%
Cash/sh	1.81	P/C	1.24	EPS next 5Y	-	ROE	-76.70%	52W Range	1.25 - 8.59	Perf YTD	4.67%
Dividend	-	P/FCF	-	EPS past 5Y	37.50%	ROI	-	52W High	-73.92%	Beta	1.72
Dividend %	-	Quick Ratio	7.20	Sales past 5Y	-	Gross Margin	-	52W Low	79.20%	ATR	0.22
Employees	20	Current Ratio	7.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	31.57	Volatility	8.37% 7.66%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	19.20%	Profit Margin	-	Rel Volume	0.13	Prev Close	2.37
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 11 AMC	Payout	-	Avg Volume	6.08M	Price	2.24
Recom	2.00	SMA20	-21.20%	SMA50	-27.25%	SMA200	-45.99%	Volume	771,671	Change	-5.49%

Mar-11-21

Upgrade

Oppenheimer

Perform → Outperform

Nov-02-20

Downgrade

Wedbush

Outperform → Neutral

Oct-27-20

Downgrade

Oppenheimer

Outperform → Perform

Oct-27-20

Downgrade

H.C. Wainwright

Buy → Neutral

Oct-01-20

Initiated

H.C. Wainwright

Buy

$24

Oct-05-17

Reiterated

Oppenheimer

Outperform

$4 → $7

Feb-02-17

Downgrade

Citigroup

Buy → Neutral

Dec-22-16

Initiated

H.C. Wainwright

Buy

$14

Jun-08-16

Reiterated

Wedbush

Outperform

$27 → $17

Jul-20-15

Initiated

Wedbush

Outperform

$27

Jul-20-15

Initiated

Oppenheimer

Outperform

$28

Jul-20-15

Initiated

Citigroup

Buy

$21

Mar-11-21 04:10PM	Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update Business Wire +14.57%
Mar-02-21 08:00AM	Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences Business Wire
Jan-29-21 10:46AM	CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today InvestorPlace +70.78%
08:00AM	Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc. Business Wire
Dec-03-20 08:56AM	Implied Volatility Surging for Catabasis (CATB) Stock Options Zacks -7.66%
Dec-02-20 08:38PM	Is Catabasis Pharmaceuticals (CATB) A Good Stock To Buy Now? Insider Monkey +28.22%
Nov-12-20 04:10PM	Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update Business Wire
Oct-28-20 07:41AM	The Daily Biotech Pulse: Sanofi-GlaxoSmithKline To Supply 200M Doses To COVID-19 Vaccine Alliance, Gilead Earnings, Biodesix Debuts Benzinga -8.33%
Oct-27-20 08:24AM	The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga -70.90%
Oct-26-20 05:00PM	Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy Business Wire -7.90%
Sep-28-20 08:00AM	Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Society Business Wire
Sep-23-20 08:00AM	Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society Business Wire
Sep-21-20 08:00AM	Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer Business Wire
Sep-10-20 08:51AM	Is Catabasis Pharmaceuticals (NASDAQ:CATB) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Sep-08-20 08:00AM	Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences Business Wire +9.40%
Sep-03-20 08:41AM	Are Options Traders Betting on a Big Move in Catabasis (CATB) Stock? Zacks
Sep-02-20 08:00AM	Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy Business Wire
Aug-25-20 08:38AM	Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 8.6% Higher Zacks -6.71%
Aug-21-20 10:35AM	Oppenheimer Says These 2 Stocks Could Surge Over 100% From Current Levels TipRanks +12.18%
Aug-10-20 04:10PM	Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress Business Wire
Aug-05-20 08:00AM	Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference Business Wire
Aug-04-20 08:00AM	Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis Business Wire +5.57%
Jul-27-20 08:00AM	Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th Business Wire
Jul-15-20 08:00AM	Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference Business Wire
Jun-29-20 04:10PM	Catabasis Joins Russell 3000® Index Business Wire
Jun-15-20 08:16PM	Hedge Funds Have Never Been This Bullish On Catabasis Pharmaceuticals Inc (CATB) Insider Monkey
Jun-12-20 08:00AM	Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel Business Wire +6.16%
May-12-20 04:10PM	Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress Business Wire
08:00AM	Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy Business Wire
May-07-20 09:30AM	These 3 Biotech Stocks Have Massive Upside Potential, Says Wedbush TipRanks
Apr-28-20 08:00AM	Catabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12th Business Wire
Apr-17-20 08:00AM	Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session Business Wire
Mar-27-20 03:22AM	Edited Transcript of CATB earnings conference call or presentation 10-Mar-20 12:30pm GMT Thomson Reuters StreetEvents
Mar-25-20 08:00AM	Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference Business Wire +5.70%
Mar-24-20 04:00PM	Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies ACCESSWIRE +12.21%
Mar-18-20 08:00AM	Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session Business Wire -15.55%
Mar-14-20 09:32AM	If You Had Bought Catabasis Pharmaceuticals (NASDAQ:CATB) Stock Three Years Ago, You'd Be Sitting On A 76% Loss, Today Simply Wall St.
Mar-10-20 08:05AM	Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business Progress Business Wire
06:30AM	Catabasis Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-25-20 08:00AM	Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments on Tuesday, March 10th Business Wire
Feb-21-20 08:00AM	Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy Business Wire
Feb-03-20 04:05PM	Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option Business Wire
Jan-30-20 09:00AM	Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering Business Wire
Jan-29-20 04:01PM	Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering Business Wire
06:10AM	Here's Why We're Watching Catabasis Pharmaceuticals's (NASDAQ:CATB) Cash Burn Situation Simply Wall St.
Jan-09-20 04:09PM	Catabasis (CATB) Partners with UK-Based Charity for DMD Study Zacks
Jan-08-20 08:00AM	Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial Business Wire
Dec-24-19 06:15AM	Is Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Fair? Simply Wall St.
Dec-23-19 02:15PM	Is Catabasis Pharmaceuticals Inc (CATB) A Good Stock To Buy? Insider Monkey +10.58%
Dec-16-19 08:00AM	Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population Business Wire
Nov-25-19 06:45PM	Edited Transcript of CATB earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-18-19 06:53AM	Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Nov-07-19 08:05AM	Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress Business Wire
Oct-24-19 08:00AM	Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th Business Wire
Oct-19-19 09:26AM	Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): When Will It Breakeven? Simply Wall St.
Oct-18-19 08:00AM	Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting Business Wire
Oct-05-19 08:00AM	Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy Business Wire
Sep-30-19 04:05PM	Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment Business Wire
Sep-27-19 08:00AM	Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society Business Wire
Sep-26-19 08:00AM	Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy Business Wire
Sep-25-19 08:00AM	Catabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial Officer Business Wire
Sep-19-19 10:13AM	How Much Of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Do Institutions Own? Simply Wall St.
Aug-20-19 10:58AM	Investors Who Bought Catabasis Pharmaceuticals (NASDAQ:CATB) Shares Three Years Ago Are Now Down 87% Simply Wall St.
Aug-09-19 05:04PM	Edited Transcript of CATB earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 08:05AM	Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress Business Wire
Aug-07-19 08:00AM	Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors Business Wire
Aug-06-19 08:00AM	Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference Business Wire
Jul-25-19 08:30AM	Catabasis Pharmaceuticals to Report Second Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, August 8th Business Wire
Jul-15-19 03:08PM	Does Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Reflect Performance? Simply Wall St.
Jun-27-19 08:00AM	Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference Business Wire
Jun-21-19 09:45AM	Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy Business Wire
Jun-18-19 08:00AM	Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference Business Wire +6.61%
Jun-07-19 09:24AM	Vertex Expands Collaboration With CRISPR, Acquires Exonics Zacks
May-15-19 06:33PM	Edited Transcript of CATB earnings conference call or presentation 14-May-19 12:30pm GMT Thomson Reuters StreetEvents +7.46%
08:38AM	SV Life Sciences Advisers, LLC Buys Catabasis Pharmaceuticals Inc, Sells KalVista ... GuruFocus.com
May-14-19 08:05AM	Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress Business Wire
May-02-19 08:00AM	Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting Business Wire
Apr-30-19 08:00AM	Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th Business Wire
Apr-26-19 03:26PM	Should You Be Concerned About Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) Historical Volatility? Simply Wall St.
Apr-12-19 11:34AM	Top Ranked Momentum Stocks to Buy for April 12th Zacks
Apr-01-19 08:00AM	Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference Business Wire
Mar-26-19 12:11PM	Proteostasis Plunges on Weak Data From Cystic Fibrosis Study Zacks
08:07AM	Will Catabasis Pharmaceuticals Continue to Surge Higher? Zacks
Mar-19-19 12:26PM	Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight Zacks
Mar-18-19 09:02AM	Rising P/E an Overlooked Criterion: 5 Top Stocks Zacks +9.54%
Mar-14-19 06:09PM	Edited Transcript of CATB earnings conference call or presentation 14-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
08:30AM	Catabasis (CATB) Beats Earnings in Q4, Revenues Nil Zacks
08:05AM	Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress Business Wire
Mar-13-19 08:00AM	Catabasis Pharmaceuticals to Present at Oppenheimers 29th Annual Healthcare Conference Business Wire
Mar-08-19 09:54AM	Townsquare (TSQ) to Report Q4 Earnings: What's in the Cards? Zacks +7.77%
Mar-07-19 08:57AM	Athersys (ATHX) Q4 Earnings: What's in Store for the Stock? Zacks
08:51AM	Is a Beat in Store for Catabasis (CATB) This Earnings Season? Zacks
Mar-06-19 01:56PM	Investors Who Bought Catabasis Pharmaceuticals Shares Three Years Ago Are Now Down 93% Simply Wall St.
Feb-28-19 08:00AM	Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14 Business Wire
Feb-19-19 08:00AM	Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy Business Wire +6.31%
Feb-14-19 08:00AM	Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors Business Wire
Feb-06-19 09:00AM	Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering Business Wire -23.64%
08:23AM	The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 04:01PM	Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering Business Wire
Jan-29-19 07:55AM	New Research: Key Drivers of Growth for Tiffany, CarMax, Cars, RPC, Cleveland-Cliffs, and Catabasis Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire

Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience